BRAF and neoplasm: In this regard, it has been suggested that BRAF/MEKi therapy—next to its cytostatic effects—might also contribute to tumor control via immunomodulatory effects, such as increasing melanoma immunogenicity, paradoxical activation of effector T cells, or reducing the infiltration of tumor-associated macrophages and myeloid-derived suppressor cells [36,37].